Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary and secondary progressive multiple sclerosis.

Sandra Vukusic1, Christian Confavreux

  • 1European Database for Multiple Sclerosis (EDMUS) Coordinating Center and Service de Neurologie A, Hôpital Neurologique, Hospices Civils de Lyon, 59 Boulevard Pinel, Lyons Cedex 03, 69394, France. sandra.vukusic@chu-lyon.fr

Journal of the Neurological Sciences
|February 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity.

Brain : a journal of neurology·2026
Same author

Updated French OFSEP recommendations for multiple sclerosis MRI: alignment with the 2024 McDonald criteria.

Journal of neuroradiology = Journal de neuroradiologie·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

Neurology·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

Journal of the neurological sciences·2026
Same journal

Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

Journal of the neurological sciences·2026
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
See all related articles

Primary progressive multiple sclerosis (PPMS) may be a distinct entity, not part of the main disease spectrum. This impacts treatment options and clinical trial eligibility for PPMS patients.

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) is a chronic neurological disease.
  • The progressive phase of MS is linked to irreversible disability.
  • Primary progressive multiple sclerosis (PPMS) presents unique challenges regarding its classification and treatment.

Purpose of the Study:

  • To determine if primary progressive MS (PPMS) is an integral part of the MS disease spectrum.
  • To investigate the clinical similarities and differences between PPMS and secondary progressive MS (SPMS).
  • To address the therapeutic orphan status of PPMS patients in clinical trials.

Main Methods:

  • Comparative analysis of clinical data from patients with different MS subtypes.
  • Review of existing literature on the progression and characteristics of MS phenotypes.

Related Experiment Videos

Main Results:

  • Discussion of clinical similarities and differences between PPMS and SPMS.
  • Highlighting the implications of PPMS classification on treatment accessibility.

Conclusions:

  • The classification of PPMS has significant implications for patient treatment and trial inclusion.
  • Further research is needed to clarify the distinct nature of PPMS within the MS spectrum.